|
Pharmacy and Therapeutics Committee
The Idaho Medicaid Pharmacy and Therapeutics Committee (P&T Committee) is comprised of Idaho health practitioners – physicians, physician assistant, pharmacists – who are committed to providing the right care at the right price. This committee meets four times per year to review clinical evidence. The P&T Committee makes recommendations to the Department of Health and Welfare regarding drug safety and efficacy as well as prior authorization requirements. Cost modeling analysis is done by the department twice per year – following the committee meetings in May and November.
Preferred Drug List (PDL)
General P&T Information
2013 Meeting Dates:
April 19
May 10
October 11
November 15
Voting Members
- Perry Brown, M.D. (Board Chairman, Boise, serving since January 2009)
- Elaine Ladd, PharmD (Boise, serving since January 2010)
- Troy Geyman, M.D. (Bonners Ferry, serving since 2012)
- Jeffrey Johnson, PA (Meridian, serving since 2011)
- Leigh Morse, M.D. (Hailey, serving since 2012)
- Kevin Ellis, PharmD (McCall, serving since 2012)
- David Calley, PharmD (Meridian, serving since 2012)
Non-Voting Members
- Mark Turner, MD (Boise, serving since January 2009)
- Tamara Eide, PharmD (Medicaid Pharmacy Supervisor)
- Mark Johnston, RPh (Idaho Board of Pharmacy)
- Hamilton Warren-Sutton, MD (Boise, Mental Health Drug Adviser since November 2011)
P&T Drug Review Schedule for 2013
Black = DERP Review
Green = Magellan/Provider Synergies
P&T Drug Review Schedule for 2013
|
P&T Meeting Dates
|
New Reviews
|
Re-Reviews
|
|
April 19, 2013 *
|
|
Androgenic Agents
Angiotensin Modulators
Angiotensin Modulator Combinations
Anticoagulants
Beta Blockers
BPH Treatments
Bladder Relaxant Preparations
Bone Resorption Suppression and Related Agents
Calcium Channel Blockers
Erythropoiesis Stimulating Proteins
Hepatitis C Agents
Hypoglycemics, Incretin Mimetics/Enhancers
Hypoglycemics, Insulin
Hypoglycemics, TZD
Growth Factors
Growth Hormone
Lipotropics, Other
Lipotropics, Statins
Pancreatic Enzymes
Phosphate Binders
Platelet Aggregation Inhibitors
Proton Pump Inhibitors
PAH Agents, Oral
|
|
May 10, 2013**
|
|
Analgesics, Narcotic long-acting
Analgesics, Narcotic short-acting
Antiemetics/Antivertigo Agents
Antibiotics, Inhaled
Antibiotics, Gastrointestinal
Antibiotics, Topical
Antibiotics, Vaginal
Antifungals, Oral
Antifungals, Topical
Antimigraine Agents
Antiparasitics, Topical
Antivirals, HSV
Antivirals, Influenza
Antivirals, Topical
Cephalosporins and Related Agents
Colony Stimulating Factors
Coronary Vasodilators
Fluroquinolones, oral
H Pylori Treatment
Immunosuppressants
Macrolides/Ketolides
Multiple Sclerosis Agents
Opiate Dependence
Skeletal Muscle Relaxants
Tetracyclines
Ulcerative Colitis Agents
|
|
October 11,
2013 ***
|
|
Antihistamines, minimally sedating
Bronchodilators, Beta Agonist
Cough and Cold
Glucocorticoids, Inhaled
Immunomodulators, Atopic Dermatitis
Intranasal Rhinitis
Leukotriene Modifiers
Ophthalmic Antibiotics
Ophthalmic Antibiotic/Steroid Combinations
Ophthalmic Antiinflammatories
Ophthalmics for Allergic Conjunctivitis
Ophthalmics, Glaucoma Agents
Otic Antibiotics
|
|
November 15, 2013****
|
|
Alzheimer's Agents
Anticonvulsants
Antidepressants, Other
Antidepressants, SSRIs
Antihyperuricemics, oral
Antiparkinson's Agents/Restless Leg Syndrome
Antipsychotics, Atypical
Antipsychotics, Typical
Cytokine/CAM Agents
COPD Agents
NSAIDs
Otic Anti-infectives & Anesthetics
Pain, Other
Sedative Hypnotics
Stimulants and Related Agents
|
*The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 13, 2013. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions are approved by the Health and Welfare Director following the May meeting. These final decisions will be effective July 1, 2013.
**The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, May 13, 2013. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions are approved by the Health and Welfare Director following this meeting. These final decisions will be effective July 1, 2013.
***The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 18, 2013. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions approved by the Health and Welfare Director following the November meeting. These final decisions will be effective January 1, 2014.
****The P&T Committee will make its recommendations for these classes immediately following each drug class review. Recommendations will be posted on this Web site by 5 p.m. (MTN Time) on Monday, November 18, 2013. The Department's final PDL decisions for these classes will not be made until financial reviews are done by department staff and PDL decisions are approved by the Health and Welfare Director following this meeting. These final decisions will be effective January 1, 2014.
|
|